Sanjeev Puri, DO
Family Medicine · Whittier, CANPI 1730420399
Payments from drug & device makers
Across 86 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$332
- Amgen$195
- AbbVie$155
- Integra Lifesciences Corporation$122
- GSK$116
- Xeris Pharmaceuticals, Inc.$100
- plus $987 from 27 others
What the payments were for
- Food & beverage$2,007100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $332 |
| Amgen | 5 | $195 |
| AbbVie | 6 | $155 |
| Integra Lifesciences Corporation | 2 | $122 |
| GSK | 4 | $116 |
| Xeris Pharmaceuticals, Inc. | 5 | $100 |
| Lilly USA, LLC | 4 | $98 |
| Alkermes, Inc. | 5 | $94 |
| Stryker | 2 | $92 |
| Neurocrine Biosciences, Inc. | 3 | $68 |
| Merck | 3 | $61 |
| Corcept Therapeutics | 2 | $53 |
| AstraZeneca | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Bayer | 2 | $39 |
| Fresenius Kabi USA, LLC | 1 | $34 |
| Edwards Lifesciences | 1 | $33 |
| Pfizer | 2 | $33 |
| Tactile Systems Technology Inc | 1 | $29 |
| Mannkind Corporation | 2 | $28 |
| Qiagen, LLC | 2 | $28 |
| Averitas Pharma Inc. | 1 | $26 |
| Acell, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $18 |
| Solventum Corporation | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$125
How this compares
$2,007 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 133 | $67,361 |
| EliquisApixaban | 165 | $62,691 |
| TrulicityDulaglutide | 23 | $24,201 |
| MyrbetriqMirabegron | 43 | $19,676 |
| RybelsusSemaglutide | 20 | $19,204 |
| OzempicSemaglutide | 18 | $17,596 |
| TivicayDolutegravir Sodium | 16 | $17,184 |
| JanuviaSitagliptin Phosphate | 33 | $14,550 |
| EntrestoSacubitril/Valsartan | 18 | $11,923 |
| MounjaroTirzepatide | 11 | $11,885 |
| XareltoRivaroxaban | 20 | $11,506 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,801 |
| FarxigaDapagliflozin Propanediol | 19 | $10,068 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $9,709 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $9,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $62,691165 claims |
| Novo NordiskRybelsus, Ozempic | $332 | $36,80038 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $98 | $36,08634 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $116 | $21,55952 claims |
| MerckJanuvia, Belsomra | $61 | $20,49846 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $19,67643 claims |
| AstraZenecaFarxiga | $49 | $10,06819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Whittier
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.